Collecting DNA From Sex Workers to One Day Identify Their Bodies
By Sarah Zhang,
The Atlantic
| 03. 27. 2017
Bioethicists studying a small program in Dallas were surprised by what they found.
Sara Katsanis, a bioethicist at Duke University, studies the complications that arise when DNA databases are used to combat crime, especially human trafficking. If a child is kidnapped and illegally placed into adoption, for example, DNA is a reliable constant for identification. From this work, she is familiar with the ethical questions that come up when a victim is asked to give up their DNA to a database.
But even so—or perhaps, especially—she was surprised to hear of a program initiated by Dallas law enforcement to collect DNA from truck-stop sex workers to solve hypothetical future crimes. The pitch was unusual and, honestly, grim. Sex workers are more likely to be victims of murder, 60 to 100 times than other women, according to some estimates. In Dallas, police were worried about unidentifiable dead bodies that turned up by the side of the highway. (The FBI has warned about serial killers working as truck drivers.) Voluntarily give a DNA sample now, the program promised, and if...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...